Atai Life Sciences initiated with an Outperform at Oppenheimer

Oppenheimer initiated coverage of Atai Life Sciences (ATAI) with an Outperform rating and $14 price target The firm says Atai is the leading the psychedelic revolution within neuropsychiatry. The market opportunity is underappreciated considering 10M patients could benefit from alternative approaches, the analyst tells investors in a research note. Atai’s Phase 2b data for BPL-003 solidify a “transformational approach,” the analyst tells investors in a research note.